Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 2007

View Archived Issues

COURAGE study finds PCI not beneficial in medically treated coronary artery disease

Promising in vivo results with a novel HPV vaccine for the treatment of cervix cancer

Snapshots: Recent findings for ceftobiprole

Studies show activity of ITMN-191 with other agents

Recent patents disclose novel agents for obesity and metabolic disorders

Recent BioTie patent claims novel therapeutic agents for thrombosis and related disorders

SurModics signs expanded corporate technology agreement with St. Jude Medical

New PMEG prodrug with improved therapeutic index designed by Gilead

ME-3738 protects against acetaminophen-induced liver injury in mice

Novel agents for treating sepsis disclosed in recent Sankyo patent

Enrollment completed for phase II osteoporosis study of NB-S101

BZL-101 begins phase I/II trial in advanced breast cancer

Protalix cleared to begin phase III study of prGCD for Gaucher's disease

SynCo and Prosensa sign service agreement for RNA therapeutics for DM

MM-093 studied in phase II for rheumatoid arthritis

Two phase II/III trials evaluate NT-501 in retinitis pigmentosa

Cortex submits Ampakine CX-717 data package to FDA

Sciele studies pravastatin and fenofibrate combination in phase II

Update on phase IIa MS study of ATL-1102

Development of new water-soluble topoisomerase I inhibitor reported by Chugai

Phase III trials planned for novel antiplatelet therapy SCH-530348

CovX designs Ang2-targeted antibody with promising antitumor activity

PF-337210, a new, selective, orally bioavailable VEGFR-2 inhibitor

ADX-10059 achieves statistically significant outcome in GERD study

Zenvia improves pain rating scale in painful diabetic neuropathy

Ostarine improves insulin resistance in elderly patients

Comtan launched in Japan

Swedish approval for Rapydan local anesthetic patch

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...